Cargando…
A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers
ACE-536, a recombinant protein containing a modified activin receptor type IIB, is being developed for the treatment of anemias caused by ineffective erythropoiesis, such as thalassemias and myelodysplastic syndromes. ACE-536 acts through a mechanism distinct from erythropoiesis-stimulating agents t...
Autores principales: | Attie, Kenneth M, Allison, Mark J, McClure, Ty, Boyd, Ingrid E, Wilson, Dawn M, Pearsall, Amelia E, Sherman, Matthew L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4173124/ https://www.ncbi.nlm.nih.gov/pubmed/24715706 http://dx.doi.org/10.1002/ajh.23732 |
Ejemplares similares
-
Locally acting ACE‐083 increases muscle volume in healthy volunteers
por: Glasser, Chad E., et al.
Publicado: (2018) -
S167: EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY
por: Gerds, Aaron T., et al.
Publicado: (2023) -
Main changes in European Clinical Trials Regulation (No 536/2014)
por: Tenti, E., et al.
Publicado: (2018) -
The pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers
por: Ashby, J, et al.
Publicado: (2010) -
536. Clostridium difficile Colonization in the First Year of Life
por: Clayton, Jason A, et al.
Publicado: (2018)